Mei Yu
Lichao Ge- The First People’s Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, China
Sarcopenia and atherosclerosis are age-related conditions pathologically intertwined through a self-reinforcing, bidirectional cycle. This review dissects the core mechanistic pillars of this synergy such as insulin resistance, chronic low-grade inflammation, ectopic lipid deposition, and hormonal dysregulation. We detail how skeletal muscle dysfunction exacerbates systemic insulin resistance and inflammatory cascades that accelerate endothelial damage and atherogenesis. Conversely, atherosclerotic vascular impairment compromises microcirculatory function, inducing muscle ischemia and metabolic decline. Beyond pathogenesis, we evaluate integrated intervention, including combined exercise, anti-inflammatory diets, and pleiotropic pharmacotherapies, that concurrently target shared pathways in muscle and vasculature. By framing this comorbidity within the context of aging hallmarks, we advocate a paradigm shift from organ-specific management toward a holistic, geroscience-based approach to mitigate frailty and disability in the aging population.
1 Introduction
Sarcopenia and atherosclerosis are major drivers of morbidity and mortality in older adults. Traditionally, they have been studied in isolation, but a burgeoning body of evidence now positions them as manifestations of a shared systemic age-associated metabolic dysfunction (1). The interplay between deteriorating muscle health and progressive vascular disease is mediated by fundamental biological processes of aging, including dysregulated nutrient sensing, mitochondrial dysfunction, and altered intercellular communication (2, 3). Traditionally studied as distinct entities, emerging evidence now reveals a complex bidirectional relationship mediated by shared metabolic pathways, including insulin resistance (IR), chronic inflammation, ectopic fat deposition, and hormonal Shifts (4–7). Epidemiological studies indicate that sarcopenia is associated with an increased risk of cardiovascular diseases (6, 8), including atherosclerosis, independent of traditional risk factors. Conversely, atherosclerosis and its risk factors, such as metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM), and visceral obesity, can accelerate muscle loss, creating a vicious cycle that exacerbates both conditions (9, 10). The interplay between skeletal muscle and vascular health is thus a critical area of research with significant implications for early intervention and holistic management. At the molecular level, IR is a central player. Skeletal muscle is a primary site for insulin-mediated glucose uptake; consequently, muscle atrophy contributes to systemic IR (11), which in turn promotes endothelial dysfunction (12). Ectopic fat deposition, particularly in the liver and muscle, is another hallmark of both conditions, driven by lipid spillover from dysfunctional adipose tissue (13–15). Chronic low-grade inflammation (“inflammaging”), characterized by elevated cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), further links muscle wasting to vascular damage (16–18). Vitamin D deficiency, common in both disorders, may also serve as a modulatory factor, influencing muscle protein synthesis and vascular inflammation (19, 20). Additionally, myokines and adipokines, such as myostatin, adiponectin, and irisin, form a cross-tissue network that regulates metabolism and inflammation, offering potential therapeutic targets (16–18). This review synthesizes current evidence on the bidirectional metabolic crosstalk between these conditions, adopting a geroscience framework to elucidate how targeting core aging mechanisms may offer synergistic benefits for both muscle and vascular health.
2 Sarcopenia and metabolic mechanism
Sarcopenia is a multifactorial syndrome driven by a complex interplay of metabolic dysregulations that create a self-perpetuating cycle of muscle wasting (21). A central mechanism is IR and compensatory hyperinsulinemia. Given that skeletal muscle accounts for approximately 80% of postprandial glucose uptake (22), its quantity and quality are fundamental determinants of systemic glucose homeostasis. Reduced muscle mass directly diminishes glucose disposal capacity, leading to hyperinsulinemia, which exerts direct catabolic effects on muscle (21). This disrupts the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, crucial for protein synthesis. Impaired insulin signaling activates forkhead box O (FoxO) transcription factors, upregulating atrophy-related genes like Atrogin-1 and MuRF-1, which promote proteasomal degradation of muscle proteins (23). Concurrently, IR increases lipolysis, elevating circulating free fatty acids (FFAs) that accumulate intramyocellularly lipids (IMCL), particularly diacylglycerols (DAGs) and ceramides (24). These lipid intermediates activate inflammatory pathways like nuclear factor-κB (NF-κB) and directly inhibit insulin signaling, further exacerbating IR (24). Beyond proteolysis, IR and aging contribute to anabolic resistance, whereby muscle becomes less responsive to the protein-synthesis-stimulating effects of both insulin and amino acids, further hindering maintenance and repair (25).
This metabolic dysfunction is exacerbated by inflammaging, characterized by elevated pro-inflammatory cytokines such as TNF-α, IL-6, and C-reactive protein (CRP) (26). TNF-α is a potent inducer of muscle wasting, activating NF-κB to stimulate MuRF-1 expression and protein breakdown (23). IL-6 can induce atrophy via the Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway and by suppressing Insulin/insulin-like growth factor-1 (IGF-1) signaling (27). In visceral obesity, dysfunctional adipose tissue infiltrated by macrophages becomes a significant source of these cytokines, creating a systemic catabolic environment for muscle (28).
Mitochondrial dysfunction is another key pillar of sarcopenia. The age-related decline in mitochondrial biogenesis, impaired oxidative phosphorylation (OXPHOS), and increased reactive oxygen species (ROS) production create an energetic deficit, compromising ATP-intensive processes like protein synthesis and sarcomere maintenance (29). Excessive ROS damages cellular components, can trigger apoptosis, and is intrinsically linked to intramuscular IR (30). These processes are compounded by hormonal changes. Vitamin D deficiency, common in aging and MetS, is associated with muscle weakness and atrophy, likely by impairing myocyte differentiation, calcium handling, and inflammation modulation (31). The age-related decline in the Growth Hormone (GH)/IGF-1 axis reduces a vital anabolic stimulus for muscle protein synthesis, as IGF-1 is a primary activator of the Protein Kinase B/Mammalian Target of Rapamycin (Akt/mTOR) pathway (32). The decline in sex hormones, particularly testosterone in men, further reduces anabolic support by directly stimulating synthesis and inhibiting breakdown (33). In addition, sex hormones not only directly regulate muscle anabolism, but also indirectly participate in the common pathological process of sarcopenia and atherosclerosis by influencing fat distribution and metabolic phenotype. Estrogen tends to promote subcutaneous storage of fat and inhibit visceral fat accumulation and inflammation, while androgens can inhibit fat differentiation and promote lipolysis at physiological levels; After menopause, women experience a sudden drop in estrogen levels, leading to a shift in fat distribution from “subcutaneous dominance” to “visceral dominance”, accompanied by increased inflammation of adipose tissue and lipid leakage (34, 35). The expansion of visceral fat not only directly activates the muscle atrophy pathway and inhibits protein synthesis by releasing inflammatory factors such as IL-6 and TNF –α (36), but also drives IR and ectopic lipid deposition in muscles, further damaging muscle mass and function (37). At the same time, FFAs from visceral fat and inflammatory mediators enter the liver through the portal vein to promote the formation of atherogenic lipoprotein profile, and cooperate with the endothelial function decline caused by estrogen loss to jointly accelerate vascular disease (38, 39). Therefore, gender differences in fat distribution regulated by sex hormones are an important link connecting muscle and vascular metabolic dysfunction.
Critically, the interplay between sarcopenia and obesity converges into a distinct clinical phenotype known as sarcopenic obesity, which represents a high-risk geriatric syndrome characterized by the co-existence of reduced muscle mass/function and excess adiposity (10, 40). This condition is not merely the sum of its components but results from a synergistic pathophysiology that accelerates both musculoskeletal and cardiometabolic decline. The core mechanisms driving sarcopenic obesity are the same shared metabolic pathways linking sarcopenia and atherosclerosis: profound IR, chronic inflammation, and ectopic lipid deposition (41, 42). In sarcopenic obesity, the loss of metabolically active muscle mass diminishes glucose disposal and basal metabolic rate, promoting further adiposity and systemic IR. Concurrently, hypertrophic and dysfunctional adipose tissue, particularly visceral fat, releases elevated levels of FFAs and pro-inflammatory cytokines that promote muscle protein breakdown via ubiquitin-proteasome activation, inhibit anabolic signaling, and induce intramyocellular lipid accumulation, thereby creating a self-perpetuating cycle of muscle loss and fat gain (43, 44).
Finally, ectopic fat deposition results from the inability of subcutaneous fat to expand healthily, leading to lipid spillover into muscle (45). IMCL and their derivatives (ceramides, DAGs) actively disrupt insulin signaling and promote inflammation (24). This infiltration is a critical determinant of muscle quality; individuals with identical muscle mass can have vastly different strength and metabolic profiles based on their degree of fatty infiltration, which weakens muscle architecture and contractile force (46) (As shown in Figure 1).
Figure 1. Schematic overview of the core metabolic pathways linking sarcopenia and atherosclerosis. This figure illustrates the four key pathophysiological pillars that create a vicious bidirectional cycle between muscle and vascular decline: (1) Systemic Insulin Resistance drives muscle atrophy and impairs vascular endothelial function. (2) Inflammaging, fueled by visceral fat and cellular senescence, simultaneously promotes muscle protein breakdown and atherosclerotic plaque progression. (3) Ectopic Lipid Deposition from adipose tissue dysfunction leads to intramyocellular lipotoxicity and promotes atherogenic dyslipidemia. (4) Hormonal Dysregulation creates a shared catabolic and pro-inflammatory state. Arrows indicate the bidirectional crosstalk and positive feedback loops that perpetuate the co-development of both conditions.
3 Atherosclerosis and metabolic mechanism
Atherosclerosis is a chronic inflammatory disease of the arterial wall, whose pathogenesis is deeply intertwined with systemic metabolic dysfunction (47). The initial insult often stems from endothelial dysfunction. Under physiological conditions, insulin promotes vasodilation by activating the PI3K/Akt pathway to stimulate endothelial nitric oxide synthase (eNOS) and increase bioavailable nitric oxide (NO) (48). In the insulin-resistant state, this pathway is selectively impaired, reducing NO bioavailability. Concurrently, other insulin signaling pathways (e.g., MAPK) remain active, driving a pathogenic shift towards increased secretion of the vasoconstrictor endothelin-1 (ET-1), upregulation of adhesion molecules (VCAM-1, ICAM-1), and elevated expression of plasminogen activator inhibitor-1 (PAI-1), fostering a pro-inflammatory, pro-thrombotic milieu that initiates atherogenesis (48).
This endothelial dysfunction is fueled by atherogenic dyslipidemia. IR drives hepatic overproduction of large, triglyceride-rich very-low-density lipoproteins (VLDL) (49). Elevated triglycerides facilitate a cholesteryl ester transfer protein (CETP)-mediated exchange, remodeling LDL into small, dense LDL (sdLDL) particles, which are highly atherogenic due to increased susceptibility to oxidation and enhanced arterial retention (49). Concomitantly, high-density lipoproteins (HDL) become triglyceride-enriched and cholesterol-depleted, transforming it from a protective particle into a dysfunctional or pro-inflammatory state (50).
The retention and oxidation of low-density lipoproteins (LDL) within the subendothelial space forms Oxidized LDL (oxLDL), a pivotal “danger signal” that triggers a robust inflammatory response (47). OxLDL activates the endothelium, promoting monocyte recruitment and differentiation into macrophages. These macrophages engulf modified lipoproteins via scavenger receptors, becoming lipid-laden “foam cells” that define the early fatty streak lesion (51). These activated immune cells secrete pro-inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α), chemokines, and growth factors that perpetuate leukocyte recruitment and drive plaque progression. Inflammation also dictates clinical outcomes; matrix metalloproteinases (MMPs) secreted by macrophages degrade the plaque’s fibrous cap, rendering it vulnerable to rupture and precipitating acute thrombotic events like myocardial infarction or stroke (47, 51).
The systemic inflammatory tone is powerfully modulated by visceral adipose tissue (VAT). In obesity, hypertrophied adipocytes and infiltrating immune cells within VAT secrete elevated levels of pro-inflammatory adipokines while suppressing protective ones like adiponectin (52, 53). Via drainage into the portal circulation, VAT floods the liver with FFAs and inflammatory mediators, exacerbating hepatic IR, promoting dyslipidemia, and stimulating the production of acute-phase proteins like CRP, thereby amplifying the systemic inflammatory burden (38, 54).
Emerging research also implicates the gut microbiome. Dietary nutrients rich in choline and L-carnitine are metabolized by gut microbes into trimethylamine, which is oxidized in the liver to trimethylamine N-oxide (TMAO). Elevated TMAO levels are associated with increased cardiovascular risk, as it promotes atherosclerosis by enhancing foam cell formation, activating inflammatory pathways, and impairing endothelial function (55) (As shown in Figure 1).
4 Shared metabolic pathways in sarcopenia and atherosclerosis
The pathophysiological convergence of sarcopenia and atherosclerosis is not merely associative but causal, creating a feed-forward loop of decline. This cycle is powered by the dysfunction of evolutionarily conserved metabolic and inflammatory pathways, which are also core pillars of the aging process itself (As shown in Table 1).
Table 1. Bidirectional metabolic mechanisms linking sarcopenia and atherosclerosis.
4.1 Insulin resistance
IR represents a fundamental and shared metabolic defect that fuels a self-perpetuating, bidirectional pathological cycle between skeletal muscle and the vasculature, thereby accelerating the progression of both sarcopenia and atherosclerosis (56, 57). Skeletal muscle, being the primary site for postprandial glucose disposal, sees its metabolic function critically impaired in sarcopenia. The reduction in muscle mass and quality directly diminishes the body’s capacity for insulin-mediated glucose clearance, leading to compensatory hyperinsulinemia (21, 58). This hyperinsulinemia is not merely a marker of compensation but an active contributor to pathology, as it exerts direct catabolic effects on muscle tissue and promotes endothelial dysfunction (58). At the molecular level within myocytes, IR disrupts the anabolic PI3K/Akt signaling pathway. This impairment not only blunts protein synthesis but also leads to the activation of FoxO transcription factors. Activated FoxO upregulates the expression of the muscle-specific E3 ubiquitin ligases Atrogin-1 and MuRF-1, orchestrating the proteasomal degradation of key contractile proteins and driving muscle atrophy (59). Concurrently, IR induces a state of anabolic resistance, whereby the skeletal muscle becomes less responsive to the protein-synthetic stimulus of both insulin and essential amino acids, further crippling its maintenance and repair capabilities (60, 61). The metabolic consequences extend beyond glucose, as IR in adipose tissue triggers enhanced lipolysis, elevating circulating FFAs. These FFAs are taken up by muscle and esterified into toxic lipid intermediates like DAGs and ceramides. DAGs activate protein kinase C (PKC) isoforms that serine-phosphorylate and inhibit the insulin receptor substrate 1 (IRS-1), while ceramides activate Protein Phosphatase 2A (PP2A), which dephosphorylates and deactivates Akt, thereby locally exacerbating IR and promoting further atrophy (56, 62).
Conversely, the impact of IR on the vascular endothelium is a primary driver of atherogenesis and directly compromises muscle health. In a state of IR, insulin signaling in endothelial cells becomes selectively impaired in the PI3K/Akt/eNOS axis. This results in reduced production of the vasoprotective molecule NO (63, 64). Critically, the MAPK pathway remains sensitized to insulin, leading to a pathological imbalance. This unchecked MAPK signaling promotes the overexpression of the potent vasoconstrictor ET-1, upregulates the expression of adhesion molecules such as VCAM-1 and ICAM-1, and increases the secretion of PAI-1. This shift creates a pro-inflammatory, pro-thrombotic, and pro-atherogenic endothelial phenotype that initiates and accelerates plaque formation (48, 65). The resulting endothelial dysfunction and the associated microvascular rarefaction significantly impair blood flow and nutrient delivery to skeletal muscle. This creates a state of relative muscle ischemia, which exacerbates metabolic stress, limits exercise capacity, and contributes to further muscle wasting, thereby directly feeding into the sarcopenic process (5, 57, 63) (As shown in Figure 2).
Figure 2. Insulin resistance as a bidirectional driver of sarcopenia and atherosclerosis. Skeletal muscle insulin resistance impairs glucose uptake and promotes atrophy, exacerbating systemic insulin resistance and hyperinsulinemia. Concurrently, vascular insulin resistance selectively impairs the PI3K/Akt/eNOS pathway, reducing NO bioavailability while promoting pro-inflammatory MAPK signaling. This results in endothelial dysfunction, reduced muscle perfusion, and a feed-forward cycle that worsens both conditions.
This intricate crosstalk establishes a feed-forward vicious cycle: sarcopenia-induced systemic IR worsens endothelial health, while vascular IR and microcirculatory impairment hinder muscle perfusion and metabolism, deepening sarcopenia.
4.2 Inflammaging
Chronic, low-grade inflammation, termed “inflammaging,” is a cornerstone of the aging process and a critical bidirectional link between sarcopenia and atherosclerosis. This persistent inflammatory state is not merely a passive association but an active driver of pathology in both muscle and vasculature, creating a self-reinforcing cycle of tissue degeneration (66, 67). The expansion and dysfunction of VAT serve as a primary hub for systemic inflammaging (68). In obesity and aging, hypertrophied adipocytes and infiltrating immune cells, particularly pro-inflammatory M1 macrophages, secrete a plethora of inflammatory mediators, including TNF-α, IL-6, and IL-1β (69, 70). This VAT-derived cytokine flood, drained into the portal circulation, perpetuates a state of chronic systemic inflammation that simultaneously attacks skeletal muscle and the arterial wall (71–74).
In skeletal muscle, these circulating cytokines activate distinct pro-atrophic pathways. TNF-α robustly activates the IκB kinase/NF-κB signaling cascade. NF-κB translocation to the nucleus directly transcribes the genes encoding MuRF-1, thereby accelerating the ubiquitin-proteasome system-mediated breakdown of myofibrillar proteins (75). IL-6, in a dualistic manner, can signal through its membrane-bound receptor or via a soluble receptor (trans-signaling). Chronic IL-6 exposure, particularly via trans-signaling, activates the JAK/STAT pathway. This leads to the upregulation of Suppressor of Cytokine Signaling 3 (SOCS3), which directly inhibits IGF-1 receptor signaling, thereby blunting the critical PI3K/Akt/mTOR anabolic pathway necessary for muscle protein synthesis and repair (76–78). Furthermore, local inflammation within the muscle milieu, characterized by M1 macrophage infiltration, impairs the function of satellite cells severely compromising the regenerative capacity of skeletal muscle in response to damage or stress (79–81).
In parallel, the same inflammatory mediators potently drive atherosclerotic progression. TNF-α and IL-1β activate the vascular endothelium, increasing the expression of adhesion molecules (e.g., VCAM-1, ICAM-1) and promoting the recruitment of monocytes into the subendothelial space (82). Within the nascent plaque, these monocytes differentiate into macrophages, which engulf oxLDL to become lipid-laden foam cells, the hallmark of early atherosclerotic lesions (83). These activated immune cells further produce additional cytokines (IL-6, TNF-α) and MMPs, the latter of which degrade the fibrous cap of advanced plaques, rendering them vulnerable to rupture and causing acute thrombotic events like myocardial infarction (84).
Cellular senescence, a state of irreversible growth arrest, is a key contributor. Senescent cells accumulate with age in both muscle and vasculature and secrete a powerful cocktail of pro-inflammatory factors, proteases, and growth factors known as the senescence-associated secretory phenotype (SASP) (3). The SASP directly promotes muscle fiber atrophy and endothelial dysfunction, creating a locally aggravated inflammatory environment (85, 86). Extracellular vesicles (EVs), including exosomes, have been identified as novel vehicles for inter-tissue communication. For instance, endothelial-derived EVs carrying specific microRNAs (e.g., miR-92a) can be taken up by skeletal muscle cells, where they suppress insulin signaling and promote atrophy. Conversely, EVs from atrophying muscle may carry pro-inflammatory cargo that can activate endothelial cells (87). The gut microbiome also plays a role; dysbiosis can lead to increased intestinal permeability, allowing bacterial lipopolysaccharide to enter the circulation, a condition known as metabolic endotoxemia, which triggers systemic inflammation through Toll-like receptor signaling, impacting both muscle and vasculature (88, 89). In summary, inflammaging is not a background phenomenon but an active pathological force. It is fueled by visceral fat and cellular senescence, transmitted via cytokines and EVs, and amplified by gut dysbiosis, which collectively dismantles muscle integrity and destabilizes the vascular wall, thereby inextricably linking the progression of sarcopenia and atherosclerosis (As shown in Figure 3).
Figure 3. Inflammaging as a critical bidirectional link between sarcopenia and atherosclerosis. Chronic inflammation, driven by visceral adipose tissue and cellular senescence, releases pro-inflammatory cytokines (TNF-α, IL-6, IL-1β). These cytokines simultaneously activate muscle catabolic pathways (NF-κB/JAK-STAT) and vascular inflammatory responses, promoting muscle protein breakdown, endothelial dysfunction, monocyte recruitment, and plaque progression, thereby creating a self-reinforcing inflammatory cycle.
4.3 Ectopic lipid deposition
Ectopic lipid deposition represents a critical physical manifestation of systemic metabolic dysregulation, wherein lipid overflow from dysfunctional adipose tissue infiltrates and compromises non-adipose organs, thereby directly linking the pathogenesis of sarcopenia and atherosclerosis (90, 91). This process, far beyond inert storage, involves the accumulation of bioactive lipid species that actively disrupt cellular signaling and fuel a bidirectional vicious cycle. The initiating event is often the failure of subcutaneous adipose tissue to expand healthily in the face of chronic energy surplus, leading to hypertrophic, hypoxic, and inflamed adipocytes. This dysfunctional state, particularly in visceral fat, results in uncontrolled lipolysis, flooding the circulation with excess FFAs (92) and setting the stage for ectopic deposition (37). The liver and skeletal muscle become primary sinks for this lipid overflow (93).
In skeletal muscle, elevated FFAs are esterified into IMCLs. While IMCLs themselves can be benign energy stores, the specific accumulation of toxic lipid intermediates like DAGs and ceramides is central to pathology (24, 37, 94). DAGs activate novel PKC isoforms, which phosphorylate IRS-1 on serine residues, blunting insulin signaling and contributing to local IR (11, 62, 95). More potently, ceramides activate PP2A and inhibit Akt, the master regulator of anabolism, directly promoting proteolysis and suppressing protein synthesis, thereby driving muscle atrophy (96, 97). This intramyocellular lipotoxicity is now recognized as a key determinant of “muscle quality,” explaining why individuals with similar muscle mass can exhibit vastly different strength and metabolic profiles. Furthermore, lipid droplets can interact with and disrupt mitochondrial membranes, inducing oxidative stress and impairing the energetic capacity necessary for muscle contraction and repair (24).
Concurrently, the liver avidly takes up the excess systemic FFAs, which serve as a substrate for the hepatic overproduction of triglyceride-rich VLDL (98). This VLDL overproduction initiates a cascade of atherogenic lipoprotein remodeling. CETP-mediated exchange transfers triglycerides from VLDL to LDL and HDL in exchange for cholesteryl esters. The resulting triglyceride-enriched LDL and HDL particles become ideal substrates for hepatic lipase, which hydrolyzes the triglycerides, generating sdLDL and small, dense HDL (98). SdLDL particles are highly atherogenic due to their increased susceptibility to oxidation, prolonged circulation half-life, and enhanced propensity for arterial wall retention (49). Meanwhile, the remodeled, dysfunctional HDL loses its capacity to promote reverse cholesterol transport and acquires pro-inflammatory properties, thus failing to protect against atherosclerosis (50, 99).
Beyond this shared origin in lipid overflow, novel mechanisms underscore the direct crosstalk. The concept of a “muscle-liver-vasculature” axis is gaining traction, where lipotoxins produced in insulin-resistant muscle (e.g., specific ceramide species) can be released into the circulation, potentially influencing hepatic VLDL secretion and directly affecting endothelial function (93, 100). Additionally, EVs derived from steatotic hepatocytes or lipid-laden muscle cells have been shown to carry specific lipid cargo (e.g., ceramides) and microRNAs that can be delivered to recipient cells, such as vascular smooth muscle cells, promoting their phenotypic switch to a pro-calcific, pro-inflammatory state, thereby accelerating atherosclerotic plaque maturation and instability (101, 102). Recent studies also highlight the role of perivascular adipose tissue (PVAT), which, when becoming dysfunctional and lipid-laden, loses its vasoprotective properties and secretes pro-inflammatory adipokines directly onto the adjacent arterial wall, creating a localized inflammatory milieu that accelerates atherosclerosis (38, 103) (As shown in Figure 4).
Figure 4. Ectopic lipid deposition drives a shared metabolic pathology between sarcopenia and atherosclerosis. Dysfunctional adipose tissue releases excess FFAs, leading to intramyocellular accumulation of toxic lipids (e.g., ceramides, DAGs) that impair insulin signaling and muscle quality. Concurrently, FFAs drive hepatic overproduction of triglyceride-rich VLDL, which is remodeled into atherogenic sdLDL. This ectopic lipid flux establishes a bidirectional link between muscle lipotoxicity and vascular lipid dysfunction.
In summary, ectopic lipid deposition is not a passive endpoint but a dynamic and interactive process. It originates from adipose tissue failure, directly impairing muscle function through lipotoxicity, and simultaneously drives atherogenic dyslipidemia. This shared pathway, amplified by emerging inter-organ communication via lipotoxins and EVs, creates a powerful metabolic link that simultaneously deteriorates muscle integrity and vascular health (104, 105).
4.4 Hormonal dysregulation
Age-related hormonal alterations create a shared endocrine milieu that predisposes to the parallel progression of sarcopenia and atherosclerosis (106, 107). This phenomenon extends beyond the decline of individual hormones, representing a state of systemic anabolic withdrawal coupled with a pro-inflammatory endocrine shift, which concurrently undermines the maintenance of muscle and vascular integrity.
Vitamin D deficiency, prevalent in aging and cardiometabolic diseases, exerts pleiotropic effects far beyond calcium metabolism. In skeletal muscle, the activation of the nuclear Vitamin D receptor (VDR) is crucial for myogenic differentiation and the maintenance of satellite cell function (108, 109). VDR signaling suppression impairs mitochondrial function and increases expression of atrophy-related genes, leading to sarcopenia (110). In the vasculature, vitamin D deficiency promotes endothelial dysfunction by upregulating the expression of pro-oxidant NADPH oxidase and downregulating eNOS, reducing NO bioavailability (111). Furthermore, it potentiates the Renin-Angiotensin-Aldosterone System (RAAS), leading to increased angiotensin II, which drives vascular inflammation, smooth muscle cell proliferation, and fibrosis, thereby accelerating atherosclerosis (112, 113). Emerging evidence also indicates that vitamin D exerts direct immunomodulatory effects, and its deficiency permits unchecked activation of the NF-κB pathway in both myocytes and vascular cells, amplifying the local inflammatory response (112, 114, 115).
The age-related decline in testosterone and estrogen represents a critical withdrawal of anabolic and vasoprotective support. In skeletal muscle, testosterone directly activates the androgen receptor to stimulate muscle protein synthesis via the Akt/mTOR pathway and inhibits key regulators of proteolysis, such as FoxO1 (116–118). Similarly, estradiol enhances muscle regenerative capacity and attenuates inflammation. Their decline thus creates a net catabolic state. In the vasculature, both hormones are pivotal for endothelial homeostasis. Testosterone and estradiol promote eNOS activation and NO production, ensuring vasodilation and inhibiting endothelial apoptosis. Estradiol, in particular, exerts potent antioxidant effects by suppressing NADPH oxidase and exerts anti-inflammatory actions by inhibiting NF-κB translocation in vascular smooth muscle cells and macrophages (119, 120). The loss of these protective effects post-menopause and in late-onset hypogonadism creates a permissive environment for oxidative stress, inflammation, and the progression of atherosclerotic plaques (121).
The senescence of the GH/IGF-1 axis results in a profound systemic anabolic deficit (122). In muscle, liver-derived and locally paracrine/autocrine IGF-1 binds to the IGF-1 receptor (IGF-1R), activating the canonical PI3K/Akt pathway to promote protein synthesis, inhibit apoptosis, and support satellite cell activity (123–125). Its decline is a central driver of anabolic resistance and muscle wasting. The vascular system is equally dependent on IGF-1 signaling. IGF-1 is a potent survival factor for endothelial cells, stimulating NO production and protecting against oxidative stress-induced apoptosis (126, 127). It also maintains vascular smooth muscle cell contractility and inhibits their pathological transition to a calcifying phenotype. The age-related decline in IGF-1 is thus associated with endothelial dysfunction, increased arterial stiffness, and enhanced susceptibility to vascular calcification (128, 129).
Beyond these classical axes, recent research highlights the role of bone-muscle cross-talk. Osteocalcin, particularly in its undercarboxylated, hormonally active form, is now recognized to promote muscle function and insulin sensitivity while also exerting protective effects on the endothelium. Age-related decline in osteocalcin may thus represent another endocrine link connecting musculoskeletal decline with vascular aging (130). Similarly, adipose-derived hormones like adiponectin, which typically exerts anti-inflammatory and insulin-sensitizing effects, decline with age and visceral obesity. Low adiponectin levels are associated with both muscle atrophy and accelerated atherosclerosis Thus, the waning of anabolic hormonal support creates a shared environment of vulnerability, predisposing to the parallel progression of muscle wasting and vascular sclerosis (131, 132), highlighting another dimension of the dysregulated endocrine network in aging (131). Moreover, the gut-muscle axis is being elucidated, with evidence suggesting that gut-derived hormones like Ghrelin may not only stimulate appetite but also have direct anti-inflammatory and anabolic effects on skeletal muscle, with potential secondary benefits for vascular health (133) (As shown in Figure 5).
Figure 5. Hormonal dysregulation creates a shared catabolic milieu for sarcopenia and atherosclerosis. Age-related declines in vitamin D, sex hormones, and IGF-1 simultaneously impair muscle anabolism (via suppressed Akt/mTOR signaling) and vascular integrity (via reduced NO bioavailability, increased oxidative stress and inflammation). This shared endocrine deficiency promotes both muscle wasting and endothelial dysfunction, accelerating the co-progression of both conditions.
In conclusion, hormonal dysregulation in aging creates a catabolic, pro-oxidant, and pro-inflammatory internal environment that simultaneously dismantles the structural and functional integrity of both skeletal muscle and the vascular system (134, 135). This shared endocrine failure provides a powerful rationale for exploring targeted hormone replacement strategies within an integrated gerotherapeutic framework.
5 Therapeutic strategies targeting shared metabolic pathways in sarcopenia and atherosclerosis
The recognition of shared pathways necessitates a shift from single-disease management to integrated strategies targeting IR, chronic inflammation, lipid dysregulation, and hormonal shifts to disrupt the bidirectional vicious cycle (4, 136) (As shown in Table 2).
Table 2. Potential integrated therapeutic strategies targeting shared metabolic pathways in sarcopenia and atherosclerosis.
5.1 Targeting IR: the central metabolic defect
Given the pivotal role of IR in both muscle and vascular dysfunction, interventions that enhance insulin sensitivity are foundational.
5.1.1 Pharmacotherapies with dual benefits
GLP-1R agonists (GLP-1RAs) like semaglutide, liraglutide and SGLT2 inhibitors (SGLT2i) like empagliflozin, dapagliflozin, originally developed for T2DM, demonstrate pleiotropic benefits for both muscle and vasculature (137–139). GLP-1 RAs improve skeletal muscle insulin signaling via the Adenosine Monophosphate-Activated Protein Kinase (AMPK)/PI3K pathway, reducing the expression of MuRF-1/Atrogin-1 (7). In parallel, they enhance endothelial function by increasing NO bioavailability and suppressing vascular inflammation (140). SGLT2i, by promoting urinary glucose excretion, ameliorate systemic IR and have been shown to reduce ectopic lipid deposition in muscle and the arterial wall, thereby addressing a key driver of the pathology in both tissues (141).
5.1.2 Exercise as a potent physiological modulator
The integration of aerobic exercise (e.g., brisk walking, cycling) and resistance training (e.g., weight lifting) provides synergistic effects. Aerobic exercise potently activates AMPK, enhancing mitochondrial biogenesis, fatty acid oxidation, and glucose uptake via GLUT4 translocation, thereby ameliorating systemic IR and reducing ectopic lipid deposition (142–146). Concurrently, resistance training directly stimulates the PI3K/Akt/mTOR pathway, promoting muscle protein synthesis and hypertrophy, while also upregulating IRS-1 expression and enhancing insulin sensitivity in muscle (144, 147). Critically, both exercise modalities improve endothelial function through increased shear stress, which upregulates eNOS expression and NO bioavailability, thereby counteracting the endothelial dysfunction central to atherosclerosis (148). Regular exercise also reduces systemic inflammation by lowering circulating levels of pro-inflammatory cytokines (e.g., TNF-α, IL-6) and stimulating the release of anti-inflammatory myokines such as irisin and interleukin-15 from muscle, which promote lipid oxidation and vascular health (149).
In older adults with sarcopenia and cardiovascular disease, combined exercise programs have demonstrated significant improvements in muscle mass, strength, gait speed, and cardiorespiratory fitness, along with reductions in carotid intima-media thickness and arterial stiffness (150, 151). Notably, exercise-induced improvements in muscle quality, are closely correlated with enhanced endothelial function and reduced systemic IR, highlighting the tissue crosstalk facilitated by regular physical activity (152, 153).
5.2 Attenuating inflammaging
Systemic low-grade inflammation is a critical connector, driven largely by VAT. Strategies to reduce inflammatory burden are therefore essential.
5.2.1 Anti-inflammatory dietary patterns
The Mediterranean diet (MedDiet), rich in polyphenols, monounsaturated fats, and fiber, exerts potent anti-inflammatory effects by modulating gut microbiota and reducing pro-inflammatory cytokines (e.g., IL-6, TNF-α, CRP) (154). The high fiber content modulates the gut microbiome to promote the production of anti-inflammatory short-chain fatty acids (SCFAs), while its rich profile of polyphenols and monounsaturated fats directly attenuates inflammatory pathways (155). The robust anti-inflammatory and cardioprotective benefits of the MedDiet, which found that supplementation with extra-virgin olive oil or nuts significantly reduced the incidence of cardiovascular events and lowered key inflammatory biomarkers (156, 157), including IL-6, TNF-α, and CRP, reducing the incidence of sarcopenia (158).
Similarly, the Dietary Approaches to Stop Hypertension (DASH) Diet, although originally designed to lower blood pressure, shares relevant anti-inflammatory properties (159). Its emphasis on foods rich in potassium, magnesium, and fiber, coupled with a reduction in saturated fat, confers significant benefits for vascular health. This nutrient profile, by mitigating chronic inflammation, is also highly relevant for preserving muscle health, thereby offering a complementary dietary approach to address the sarcopenia-atherosclerosis comorbidity (160, 161).
5.2.2 Bioactive nutrients and supplements
Long-chain omega-3 polyunsaturated fatty acids (EPA and DHA) attenuate inflammation by competing with arachidonic acid for eicosanoid synthesis and promoting the production of specialized pro-resolving mediators (SPMs) such as resolvins (162, 163). Clinically, supplementation with these fatty acids has been demonstrated to attenuate muscle loss in older adults and slow the progression of atherosclerotic plaques (133, 164, 165).
Adequate high-quality protein intake, particularly leucine-rich sources like whey, stimulates muscle protein synthesis via mTOR activation, countering anabolic resistance (166–168). Furthermore, certain amino acids like arginine support vascular health by serving as a precursor for nitric oxide, a molecule essential for endothelial function (169). Additionally, dietary fiber fermented into SCFAs exerts systemic anti-inflammatory effects via G protein-coupled receptor signaling and Histone Deacetylase inhibition (170–172). Vitamin D supplementation corrects deficiency-related inflammation by modulating NF-κB and RAAS pathways, thereby improving muscle function and endothelial health (114, 173–176). Polyphenols and minerals (magnesium, zinc) further support anti-inflammatory and antioxidant defenses, protecting both muscle and vasculature (177–181).
5.3 Correcting lipid dysregulation and ectopic fat deposition
5.3.1 Advanced lipid-lowering agents
PCSK9 inhibitors (e.g., evolocumab) not only reduce LDL-C but also attenuate oxLDL-induced macrophage inflammation and may decrease intramyocellular lipid accumulation, improving muscle quality (182). Novel agents like olezarsen target apolipoprotein C-III to reduce triglyceride-rich lipoproteins and VLDL-C, addressing the lipid overflow that drives ectopic fat deposition (183).
5.3.2 Synthetic biology approaches
Closed-loop gene circuits such as the CHARM system represent an innovative strategy for long-term metabolic regulation. This implantable device senses cholesterol levels and auto-regulates PCSK9 inhibition, normalizing lipid profiles and reducing ectopic fat in preclinical models, offering a potential “set-and-forget” therapeutic platform (182).
5.4 Hormonal modulation
Given the role of hormonal decline in both sarcopenia and atherosclerosis, vitamin D and sex hormone replacement therapies hold promise when carefully indicated. Testosterone and estrogen support anabolic signaling via Akt/mTOR in muscle and enhance endothelial NO synthesis in vasculature (116–119, 122, 126, 127). GH/IGF-1 axis modulation may also benefit muscle protein synthesis and vascular repair, though clinical applications require further validation (123–125, 128, 129).
6 Conclusion and perspectives
The intricate comorbidity of sarcopenia and atherosclerosis represents a paradigm of multimorbidity rooted in the biology of aging. This review has delineated the bidirectional metabolic crosstalk that fuels a vicious cycle of escalating disability. The clinical imperative is clear: a shift from siloed, disease-specific management toward integrated, mechanism-based interventions that target the shared pillars of aging (21, 26, 37, 38, 47, 183). Emerging evidence underscores the necessity of moving beyond organ-specific approaches toward integrated therapeutic strategies (4). Interventions such as combined exercise training, anti-inflammatory diets (e.g., Mediterranean or DASH diet) (160, 161, 184, 185), and pharmacotherapies with pleiotropic benefits, including GLP-1RAs and SGLT2i (137–139), show promise in simultaneously targeting muscle and vascular health. Additionally, nutritional supplementation with omega-3 fatty acids (162, 163), vitamin D (114, 173–176), and high-quality protein (166–168) may help mitigate anabolic resistance and systemic inflammation (As shown in Figure 2).
In conclusion, embracing the geroscience hypothesis, which posits that targeting core aging mechanisms can mitigate multiple age-related diseases, which is paramount for disrupting the vicious cycle linking sarcopenia and atherosclerosis. Future research and clinical translation should be guided by a multi-pronged roadmap targeting fundamental pillars of aging. The clearance of senescent cells via senolytics (e.g., dasatinib/quercetin, fisetin) presents a transformative strategy to attenuate the pro-inflammatory and pro-catabolic SASP that damages both muscle and vasculature, with several clinical trials already underway (2, 3). The integration of multi-omics technologies (proteomics, metabolomics) is unlocking deep phenotyping capabilities, enabling the discovery of novel biomarkers (e.g., specific myokine profiles or gut microbiome-derived metabolites like TMAO) and paving the way for precision geriatrics (55, 186). Concurrently, advanced molecular therapeutics are emerging, including mitophagy inducers (e.g., urolithin A, nicotinamide riboside) to restore mitochondrial quality control (187, 188), gut microbiome engineering to reduce systemic inflammation (189), and innovative RNA therapeutics and gene circuits (e.g., olezarsen, the CHARM system) for long-term management of dyslipidemia (182, 183). Optimizing integrated lifestyle interventions through rigorously defined “doses” of combined exercise and targeted nutrition (e.g., leucine, omega-3s) remains a foundational and potent approach for at-risk older adults (1). Ultimately, by reconceptualizing sarcopenia and atherosclerosis as common downstream outcomes of accelerated organismal aging rather than distinct entities, we can shift the therapeutic paradigm from reactive disease management to proactive targeting of the biological roots of aging, thereby dramatically expanding the health span of our global population.
Author contributions
MY: Conceptualization, Writing – original draft, Writing – review & editing. LG: Writing – review & editing. CF: Supervision, Writing – original draft, Writing – review & editing. RZ: Supervision, Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was sponsored by the Hangzhou Medical and Health Science and Technology Project (No. B20262991).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Glossary
VDR: Vitamin D receptor
PP2A: Protein Phosphatase 2A
SASP: Senescence-associated secretory phenotype
EVs: Extracellular vesicles
Met-S: metabolic syndrome
T2DM: type 2 diabetes mellitus
CRP: C-reactive protein
IGF-1: Insulin/insulin-like growth factor-1
IGF-1R: IGF-1 receptor
ROS: Reactive Oxygen Species
mtROS: mitochondrial ROS
NADPH: Nicotinamide Adenine Dinucleotide Phosphate
PI3K: Phosphoinositide 3-kinase
IL-1β: Interleukin-1 beta
IL-6: Interleukin-6
TNF-α: Tumor Necrosis Factor-alpha
GH: Growth Hormone
NF-κB: Nuclear Factor-κB
RAAS: Renin-Angiotensin-Aldosterone System
IR: insulin resistance
JAK/STAT: Janus kinase-signal transducer and activator of transcription
OXPHOS: Oxidative phosphorylation
NO: nitric oxide
eNOS: endothelial nitric oxide synthase
PAI-1: Plasminogen activator inhibitor-1
DAGs: Diacylglycerols
VCAM-1: Vascular Cell Adhesion Molecule-1
ICAM-1: Intercellular Adhesion Molecule-1
AKT/mTOR: Protein Kinase B/Mammalian Target of Rapamycin
ET-1: endothelin-1
VLDL: very-low-density lipoproteins
oxLDL: oxidized low-density lipoproteins
GLP-1: Glucagon-Like Peptide-1
SGLT2: sodium-dependent glucose transporter 2
AMPK: Adenosine Monophosphate - Activated Protein Kinase
CETP: cholesteryl ester transfer protein
MMPs: matrix metalloproteinases
VAT: visceral adipose tissue
PVAT: perivascular adipose tissue
IMCL: Intramyocellular Lipids
TMAO: trimethylamine N-oxide
MedDiet: Mediterranean diet
DASH: Dietary Approaches to Stop Hypertension
FoxO: Forkhead Box O
IL-6R: interleukin-6 receptor
sdLDL: Small-dense LDL
SCFAs: short-chain fatty acids
SPMs: Specialized pro-resolving mediators
References
1. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, and Kroemer G. Hallmarks of aging: An expanding universe. Cell. (2023) 186:243–78. doi: 10.1016/j.cell.2022.11.001
2. Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. (2019) 40:554–63. doi: 10.1016/j.ebiom.2018.12.052
3. Kirkland JL and Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. (2020) 288:518–36. doi: 10.1111/joim.13141
4. Anagnostou D, Theodorakis N, Hitas C, Kreouzi M, Pantos I, Vamvakou G, et al. Sarcopenia and cardiogeriatrics: the links between skeletal muscle decline and cardiovascular aging. Nutrients. (2025) 17:282–300. doi: 10.3390/nu17020282
5. Hong SH and Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences. Int J Mol Sci. (2020) 21(2):494. doi: 10.3390/ijms21020494
6. Bing S, Zhanchao C, Di W, Bo Y, Hongbin Q, Yiying Z, et al. Evolution of sarcopenia status and risk of incident cardiovascular disease. Eur J Prev Cardiol. (2025) zwaf115. doi: 10.1093/eurjpc/zwaf115
7. Wang HL, Li LL, Tang ZY, Yuan Z, Jing Z, Lin Z, et al. Research progress of sarcopenia: Diagnostic advancements, molecular mechanisms, and therapeutic strategies. Exp Mol Pathol. (2025) 143:104992. doi: 10.1016/j.yexmp.2025.104992
8. Chen Y, Zhong Z, Prokopidis K, Ying G, McDowell G, Yang L, et al. Associations of sarcopenia and its components with cardiovascular risk: five-year longitudinal evidence from China health and retirement longitudinal study. J Am Heart Assoc. (2025) 14:e040099. doi: 10.1161/JAHA.124.040099
9. Tang W, Jiao Y, Kefeng Y, Jie J, Xuanxia M, Fangfang S, et al. Association between sarcopenia and components of metabolic syndrome among Chinese older adults: a population-based longitudinal study using CHARLS. BMC Public Health. (2025) 25:2823. doi: 10.1186/s12889-025-24090-4
10. Yongai L, Yingqi W, Jianxuan G, Tong M, and Huabin Y. Associations between sarcopenic, obesity, and sarcopenic obesity and metabolic syndrome in adults aged 45 Years or older: A prospective cohort study from the China health and retirement longitudinal study. Clin Nutr. (2025) 49:69–76. doi: 10.1016/j.clnu.2025.04.003
11. James DE, Stockli J, and Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol. (2021) 22:751–71. doi: 10.1038/s41580-021-00390-6
12. Espino-Gonzalez E, Dalbram E, Mounier R, Gondin J, Farup J, Jessen N, et al. Impaired skeletal muscle regeneration in diabetes: From cellular and molecular mechanisms to novel treatments. Cell Metab. (2024) 36:1204–36. doi: 10.1016/j.cmet.2024.02.014
13. Jiaqiang L, Yi W, Jinxin M, Ying Y, and Peng L. Features, functions, and associated diseases of visceral and ectopic fat: a comprehensive review. Obes (Silver Spring). (2025) 33:825–38. doi: 10.1002/oby.24239
14. Jing M, Shenglian G, Shijun G, Quan Z, Fang Y, Haifeng Z, et al. Visceral fat area is more strongly associated with arterial stiffness than abdominal subcutaneous fat area in Chinese patients with type 2 diabetes. Diabetol Metab Syndr. (2024) 16:123. doi: 10.1186/s13098-024-01356-2
15. Pellegrinelli V. Human adipocytes induce inflammation and atrophy in muscle cells during obesity. Diabetes. (2015) 64:3121–34. doi: 10.2337/db14-0796
16. Jinghong Y, Jun Z, Yimin D, Jialin L, Zhong L, Yanshi L, et al. Bioinformatics analysis based on microarray data reveals molecular crosstalk and immune relationship between sarcopenia and atherosclerosis. Exp Gerontol. (2025) 208:112811. doi: 10.1016/j.exger.2025.112811
17. Xian D, Wei H, Juan P, Ting-Ting Z, Xiao-Lei S, Xiang-Yu Z, et al. Irisin alleviates advanced glycation end products-induced inflammation and endothelial dysfunction via inhibiting ROS-NLRP3 inflammasome signaling. Inflammation. (2018) 41:260–75. doi: 10.1007/s10753-017-0685-3
18. Alcalde-Estévez E, Moreno-Piedra A, Asenjo-Bueno A, Martos-Elvira M, de la Serna-Soto M, Ruiz-Ortega M, et al. Aging-related hyperphosphatemia triggers the release of TNF-alpha from macrophages, promoting indicators of sarcopenia through the reduction of IL-15 expression in skeletal muscle. Life Sci. (2025) 368:123507. doi: 10.1016/j.lfs.2025.123507
19. Ying Z, Ming J, Jin-Yu S, Chen C, Hui S, Wei S, et al. The association between vitamin D levels and the 10-year risk of atherosclerotic cardiovascular disease: A population-based study. J Cardiovasc Nurs. (2023) 38:E178–86. doi: 10.1097/JCN.0000000000000943
20. Tingting S, Yilun W, Yuqing Z, Lane NE, Changjun L, Wei J, et al. Genetic variants, serum 25-hydroxyvitamin D levels, and sarcopenia: A mendelian randomization analysis. JAMA Netw Open. (2023) 6:e2331558. doi: 10.1001/jamanetworkopen.2023.31558
21. Cleasby ME, Jamieson PM, and Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol. (2016) 229:R67–81. doi: 10.1530/JOE-15-0533
22. DeFronzo RA and Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. (2009) 32 Suppl 2:S157–63. doi: 10.2337/dc09-S302
23. Bonaldo P and Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech. (2013) 6:25–39. doi: 10.1242/dmm.010389
24. Coen PM and Goodpaster BH. Role of intramyocelluar lipids in human health. Trends Endocrinol Metab. (2012) 23:391–8. doi: 10.1016/j.tem.2012.05.009
25. Fry CS and Rasmussen BB. Skeletal muscle protein balance and metabolism in the elderly. Curr Aging Sci. (2011) 4:260–8. doi: 10.2174/1874609811104030260
26. Franceschi C, Garagnani P, Parini P, Giuliani C, and Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. (2018) 14:576–90. doi: 10.1038/s41574-018-0059-4
27. Haddad F, Zaldivar F, Cooper DM, and Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol (1985). (2005) 98:911–7. doi: 10.1152/japplphysiol.01026.2004
28. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. (2003) 112:1796–808. doi: 10.1172/JCI200319246
29. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, and Kroemer G. The hallmarks of aging. Cell. (2013) 153:1194–217. doi: 10.1016/j.cell.2013.05.039
30. Anderson EJ and Neufer PD. Type II skeletal myofibers possess unique properties that potentiate mitochondrial H(2)O(2) generation. Am J Physiol Cell Physiol. (2006) 290:C844–51. doi: 10.1152/ajpcell.00402.2005
31. Remelli F, Vitali A, Zurlo A, and Volpato S. Vitamin D deficiency and sarcopenia in older persons. Nutrients. (2019) 11(12):2861. doi: 10.3390/nu11122861
32. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. (2008) 154:557–68. doi: 10.1038/bjp.2008.153
33. Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. (1995) 269:E820–6. doi: 10.1152/ajpendo.1995.269.5.E820
34. Palmer BF and Clegg DJ. The sexual dimorphism of obesity. Mol Cell Endocrinol. (2015) 402:113–9. doi: 10.1016/j.mce.2014.11.029
35. Karastergiou K, Smith SR, Greenberg AS, and Fried SK. Sex differences in human adipose tissues - the biology of pear shape. Biol Sex Differ. (2012) 3:13. doi: 10.1186/2042-6410-3-13
36. Tchkonia T, Thomou T, Zhu Y, Karagiannides I, Pothoulakis C, Jensen MD, et al. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab. (2013) 17:644–56. doi: 10.1016/j.cmet.2013.03.008
37. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. (2014) 371:1131–41. doi: 10.1056/NEJMra1011035
38. Neeland IJ, Ross R, Després JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. (2019) 7:715–25. doi: 10.1016/S2213-8587(19)30084-1
39. Morselli E, Santos RS, Criollo A, Nelson MD, Palmer BF, Clegg DJ, et al. The effects of oestrogens and their receptors on cardiometabolic health. Nat Rev Endocrinol. (2017) 13:352–64. doi: 10.1038/nrendo.2017.12
40. Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. (2022) 15:321–35. doi: 10.1159/000521241
41. Thornell LE. Sarcopenic obesity: satellite cells in the aging muscle. Curr Opin Clin Nutr Metab Care. (2011) 14:22–7. doi: 10.1097/MCO.0b013e3283412260
42. Poggiogalle E, Lubrano C, Sergi G, Coin A, Gnessi L, Mariani S, et al. Sarcopenic obesity and metabolic syndrome in adult caucasian subjects. J Nutr Health Aging. (2016) 20:958–63. doi: 10.1007/s12603-015-0638-1
43. Nishikawa H, Asai A, Fukunishi S, Nishiguchi S, and Higuchi K. Metabolic syndrome and sarcopenia. Nutrients. (2021) 13(10):3519. doi: 10.3390/nu13103519
44. Zamboni M, Mazzali G, Brunelli A, Saatchi T, Urbani S, Giani A, et al. The role of crosstalk between adipose cells and myocytes in the pathogenesis of sarcopenic obesity in the elderly. Cells. (2022) 11(21):3361. doi: 10.3390/cells11213361
45. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. (2009) 360:1518–25. doi: 10.1056/NEJMoa0808949
46. Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, et al. Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. J Appl Physiol (1985). (2001) 90:2157–65. doi: 10.1152/jappl.2001.90.6.2157
47. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. (2019) 5:56. doi: 10.1038/s41572-019-0106-z
48. Rask-Madsen C and King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. (2013) 17:20–33. doi: 10.1016/j.cmet.2012.11.012
49. Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. (2021) 42:4791–806. doi: 10.1093/eurheartj/ehab551
50. Rosenson RS, Brewer HB, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. (2016) 13:48–60. doi: 10.1038/nrcardio.2015.124
51. Wolf D and Ley K. Immunity and inflammation in atherosclerosis. Circ Res. (2019) 124:315–27. doi: 10.1161/CIRCRESAHA.118.313591
52. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. (1999) 257:79–83. doi: 10.1006/bbrc.1999.0255
53. Hata M, Andriessen EMMA, Hata M, Diaz-Marin R, Fournier F, Crespo-Garcia S, et al. Past history of obesity triggers persistent epigenetic changes in innate immunity and exacerbates neuroinflammation. Science. (2023) 379:45–62. doi: 10.1126/science.abj8894
54. U-Din M, Ahmed BA, Syed SA, Ong FJ, Oreskovich SM, Gunn E, et al. Characteristics of abdominal visceral adipose tissue, metabolic health and the gut microbiome in adults. J Clin Endocrinol Metab. (2024) 109:680–90. doi: 10.1210/clinem/dgad604
55. Ahmadmehrabi S and Tang WHW. Gut microbiome and its role in cardiovascular diseases. Curr Opin Cardiol. (2017) 32:761–6. doi: 10.1097/HCO.0000000000000445
56. Dada A, Habibi J, Naz H, Chen D, Lastra G, Bostick BP, et al. Enhanced ECCD36 signaling promotes skeletal muscle insulin resistance in female mice. Am J Physiol Endocrinol Metab. (2024) 327:E533–43. doi: 10.1152/ajpendo.00246.2024
57. Islam MT, Jinjin C, Allen S, Moreno DG, Bloom SI, Bramwell RC, et al. Endothelial-specific reduction in arf6 impairs insulin-stimulated vasodilation and skeletal muscle blood flow resulting in systemic insulin resistance in mice. Arterioscler Thromb Vasc Biol. (2024) 44:1101–13. doi: 10.1161/ATVBAHA.123.319375
58. Turner MC, Martin NRW, Player DJ, Ferguson RA, Wheeler P, Green CJ, et al. Characterising hyperinsulinemia-induced insulin resistance in human skeletal muscle cells. J Mol Endocrinol. (2020) 64:125–32. doi: 10.1530/JME-19-0169
59. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. (2004) 117:399–412. doi: 10.1016/S0092-8674(04)00400-3
60. Wilkinson DJ, Piasecki M, and Atherton PJ. The age-related loss of skeletal muscle mass and function: Measurement and physiology of muscle fibre atrophy and muscle fibre loss in humans. Ageing Res Rev. (2018) 47:123–32. doi: 10.1016/j.arr.2018.07.005
61. Yingfeng Z, Yina W, Zhu M, Bin L, Haitao Q, Hongquan X, et al. Vitamin K2 alleviates insulin resistance associated skeletal muscle atrophy via the AKT/mTOR signalling pathway. J Cachexia Sarcopenia Muscle. (2025) 16:e13840. doi: 10.1002/jcsm.13840
62. Petersen MC and Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. (2018) 98:2133–223. doi: 10.1152/physrev.00063.2017
63. Muniyappa R, Chen H, Montagnani M, Sherman A, and Quon MJ. Endothelial dysfunction due to selective insulin resistance in vascular endothelium: insights from mechanistic modeling. Am J Physiol Endocrinol Metab. (2020) 319:E629–46. doi: 10.1152/ajpendo.00247.2020
64. Tan J, Li X, and Dou N. Insulin resistance triggers atherosclerosis: caveolin 1 cooperates with PKCzeta to block insulin signaling in vascular endothelial cells. Cardiovasc Drugs Ther. (2024) 38:885–93. doi: 10.1007/s10557-023-07477-6
65. Wang S, Wang F, Yang L, Li Q, Huang Y, Cheng Z, et al. Effects of coal-fired PM(2.5) on the expression levels of atherosclerosis-related proteins and the phosphorylation level of MAPK in ApoE(-/-) mice. BMC Pharmacol Toxicol. (2020) 21:34. doi: 10.1186/s40360-020-00411-8
66. Ying C, Shangjin L, Ziyi C, Runzhi Y, Yongqian F, Jie C, et al. The role of chronic low-grade inflammation in the development of sarcopenia: Advances in molecular mechanisms. Int Immunopharmacol. (2025) 147:114056. doi: 10.1016/j.intimp.2025.114056
67. Młynarska E, Kowalik A, Krajewska A, Krupińska N, Marcinkowska W, Motor J, et al. Inflammaging and senescence-driven extracellular matrix remodeling in age-associated cardiovascular disease. Biomolecules. (2025) 15(10):1452. doi: 10.3390/biom15101452
68. Wernstedt Asterholm I, Tao C, Morley TS, Wang QA, Delgado-Lopez F, Wang ZV, et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. (2014) 20:103–18. doi: 10.1016/j.cmet.2014.05.005
69. Jianrui S, Farris D, Ariza P, Moorjani S, Varghese M, Blin M, et al. Age-associated adipose tissue inflammation promotes monocyte chemotaxis and enhances atherosclerosis. Aging Cell. (2023) 22:e13783. doi: 10.1111/acel.13783
70. Shih WC, Jang IH, Kruglov V, Dickey D, Cholensky S, Bernlohr DA71, et al. Role for BLT1 in regulating inflammation within adipose tissue immune cells of aged mice. Immun Ageing. (2024) 21:57. doi: 10.1186/s12979-024-00461-0
71. Li J, et al. Adipocytes orchestrate obesity-related chronic inflammation through beta2-microglobulin. Signal Transduct Target Ther. (2025) 10:394. doi: 10.1038/s41392-025-02486-3
72. Fontana L, Eagon JC, Trujillo ME, Scherer PE, and Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. (2007) 56:1010–3. doi: 10.2337/db06-1656
73. Hajer GR, van Haeften TW, and Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. (2008) 29:2959–71. doi: 10.1093/eurheartj/ehn387
74. Okamura T, Hamaguchi M, Kobayashi G, Ichikawa T, Hasegawa Y, Miyoshi T, et al. A multi-omics approach to overeating and inactivity-induced muscle atrophy in db/db mice. J Cachexia Sarcopenia Muscle. (2024) 15:2030–45. doi: 10.1002/jcsm.13550
75. Bae T, Jang J, Lee H, Song J, Chae S, Park M, et al. Paeonia lactiflora root extract suppresses cancer cachexia by down-regulating muscular NF-kappaB signalling and muscle-specific E3 ubiquitin ligases in cancer-bearing mice. J Ethnopharmacol. (2020) 246:112222. doi: 10.1016/j.jep.2019.112222
76. Baran P, Hansen S, Waetzig GH, Akbarzadeh M, Lamertz L, Huber HJ, et al. The balance of interleukin (IL)-6, IL-6.soluble IL-6 receptor (sIL-6R), and IL-6.sIL-6R.sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem. (2018) 293:6762–75. doi: 10.1074/jbc.RA117.001163
77. Rupert JE, Narasimhan A, Jengelley DHA, Jiang Y, Liu J, Au E, et al. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J Exp Med. (2021) 218(6):e20190450. doi: 10.1084/jem.20190450
78. Stahl A, Joyal JS, Chen J, Sapieha P, Juan AM, Hatton CJ, et al. SOCS3 is an endogenous inhibitor of pathologic angiogenesis. Blood. (2012) 120:2925–9. doi: 10.1182/blood-2012-04-422527
79. Zhou J, Liu Y, and Wu J. Association between immune cells, inflammatory cytokines, and sarcopenia: Insights from a Mendelian randomization analysis. Arch Gerontol Geriatr. (2025) 128:105560. doi: 10.1016/j.archger.2024.105560
80. Lu H, Huang D, Ransohoff RM, and Zhou L. Acute skeletal muscle injury: CCL2 expression by both monocytes and injured muscle is required for repair. FASEB J. (2011) 25:3344–55. doi: 10.1096/fj.10-178939
81. Lo JHT, U KP, Yiu T, On MTY, and Lee WYW. Sarcopenia: Current treatments and new regenerative therapeutic approaches. J Orthop Translat. (2020) 23:38–52. doi: 10.1016/j.jot.2020.04.002
82. Depuydt MAC, Prange KHM, Slenders L, Örd T, Elbersen D, Boltjes A, et al. Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics. Circ Res. (2020) 127:1437–55. doi: 10.1161/CIRCRESAHA.120.316770
83. Zhang C, Zhang Y, Yu Y, Zhou M, Zhang J, Fu K, et al. Macrophage-endothelial cell crosstalk drives atherosclerotic plaque formation and progression. Eur J Pharmacol. (2025) 1003:177879. doi: 10.1016/j.ejphar.2025.177879
84. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. (2005) 85:1–31. doi: 10.1152/physrev.00048.2003
85. Li X, Chen M, Chen X, He X, Li X, Wei H, et al. TRAP1 drives smooth muscle cell senescence and promotes atherosclerosis via HDAC3-primed histone H4 lysine 12 lactylation. Eur Heart J. (2024) 45:4219–35. doi: 10.1093/eurheartj/ehae379
86. Li Y, Li C, Zhou Q, Liu X, Qiao Y, Xie T, et al. Multiomics and cellular senescence profiling of aging human skeletal muscle uncovers Maraviroc as a senotherapeutic approach for sarcopenia. Nat Commun. (2025) 16:6207. doi: 10.1038/s41467-025-61403-y
87. Tang Y, Yang LJ, Liu H, Song YJ, Yang QQ, Liu Y, et al. Exosomal miR-27b-3p secreted by visceral adipocytes contributes to endothelial inflammation and atherogenesis. Cell Rep. (2023) 42:111948. doi: 10.1016/j.celrep.2022.111948
88. Ma N, Ma D, Liu X, Zhao L, Ma L, Ma D, et al. Bisphenol P exposure in C57BL/6 mice caused gut microbiota dysbiosis and induced intestinal barrier disruption via LPS/TLR4/NF-kappaB signaling pathway. Environ Int. (2023) 175:107949. doi: 10.1016/j.envint.2023.107949
89. Violi F, Castellani V, Menichelli D, Pignatelli P, and Pastori D. Gut barrier dysfunction and endotoxemia in heart failure: A dangerous connubium? Am Heart J. (2023) 264:40–8. doi: 10.1016/j.ahj.2023.06.002
90. Li CW, Yu K, Shyh-Chang N, Li GX, Jiang LJ, Yu SL, et al. Circulating factors associated with sarcopenia during ageing and after intensive lifestyle intervention. J Cachexia Sarcopenia Muscle. (2019) 10:586–600. doi: 10.1002/jcsm.12417
91. Jieying Z, Yuxin Z, Yan G, Mengjie J, Yajie G, Xinting L, et al. Biomimetic ginsenoside rb1 and probucol co-assembled nanoparticles for targeted atherosclerosis therapy via inhibition of oxidative stress, inflammation, and lipid deposition. ACS Nano. (2025) 19:22968–87. doi: 10.1021/acsnano.5c02492
92. Miranda AMA, McAllan L, Mazzei G, Andrew I, Davies I, Ertugrul M, et al. Selective remodelling of the adipose niche in obesity and weight loss. Nature. (2025) 644:769–79. doi: 10.1038/s41586-025-09233-2
93. Gengatharan JM, Handzlik MK, Chih ZY, Ruchhoeft ML, Secrest P, Ashleyet EL, et al. Altered sphingolipid biosynthetic flux and lipoprotein trafficking contribute to trans-fat-induced atherosclerosis. Cell Metab. (2025) 37:274–290 e9. doi: 10.1016/j.cmet.2024.10.016
94. Xu Z, Wenjing Y, Wentao C, Yanbing Z, Qiuyun N, Valencak TG, et al. Single-cell RNA sequencing and lipidomics reveal cell and lipid dynamics of fat infiltration in skeletal muscle. J Cachexia Sarcopenia Muscle. (2021) 12:109–29. doi: 10.1002/jcsm.12643
95. Hua-Lin Z, Grimmett ZW, Venetos NM, Stomberski CT, Qian Z, McLaughlin PJ96, et al. An enzyme that selectively S-nitrosylates proteins to regulate insulin signaling. Cell. (2023) 186:5812–5825 e21. doi: 10.1016/j.cell.2023.11.009
96. Obanda DN, et al. An extract of Urtica dioica L. mitigates obesity induced insulin resistance in mice skeletal muscle via protein phosphatase 2A (PP2A). Sci Rep. (2016) 6:22222. doi: 10.1038/srep22222
97. Petrache I and Berdyshev EV. Ceramide signaling and metabolism in pathophysiological states of the lung. Annu Rev Physiol. (2016) 78:463–80. doi: 10.1146/annurev-physiol-021115-105221
98. Kuang DD, Zhang T, Guo XY, Pan LH, Li QM, Luo JP, et al. Tea polysaccharide ameliorates atherosclerosis by inhibiting insulin resistance-mediated hepatic VLDL overproduction. J Agric Food Chem. (2025) 73:8959–77. doi: 10.1021/acs.jafc.4c11144
99. Hu S, Zhu Y, Zhao XJ, Li R, Shao GZ, Gong DX, et al. Hepatocytic lipocalin-2 controls HDL metabolism and atherosclerosis via Nedd4-1-SR-BI axis in mice. Dev Cell. (2023) 58:2326–2337 e5. doi: 10.1016/j.devcel.2023.09.007
100. Zhang J, Sjøberg KA, Gong S, Wang T, Li F, Kuo A, et al. Endothelial metabolic control of insulin sensitivity through resident macrophages. Cell Metab. (2024) 36:2383–2401 e9. doi: 10.1016/j.cmet.2024.08.008
101. Nicholls SJ and Nelson AJ. HDL and cardiovascular disease. Pathology. (2019) 51:142–7. doi: 10.1016/j.pathol.2018.10.017
102. Chen X, Chen S, Pang J, Huang R, You Y, Zhang H, et al. Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux. J Hepatol. (2023) 79:1491–501. doi: 10.1016/j.jhep.2023.08.023
103. Hof A, Landerer M, Peitsmeyer P, Herzog R, Alber J, Ahdab M, et al. Myeloperoxidase impacts vascular function by altering perivascular adipocytes' secretome and phenotype in obesity. Cell Rep Med. (2025) 6:102087. doi: 10.1016/j.xcrm.2025.102087
104. Yang XF and Shang DJ. The role of peroxisome proliferator-activated receptor gamma in lipid metabolism and inflammation in atherosclerosis. Cell Biol Int. (2023) 47:1469–87. doi: 10.1002/cbin.12065
105. Monteiro R and Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflammation. (2010) 2010:289645. doi: 10.1155/2010/289645
106. Dalle S, Rossmeislova L, and Koppo K. The role of inflammation in age-related sarcopenia. Front Physiol. (2017) 8:1045. doi: 10.3389/fphys.2017.01045
107. Alugoju P, Swamy VKD, Anthikapalli NVA, and Tencomnao T. Health benefits of astaxanthin against age-related diseases of multiple organs: A comprehensive review. Crit Rev Food Sci Nutr. (2023) 63:10709–74. doi: 10.1080/10408398.2022.2084600
108. Wu W, Zhou JC, and Yang L. Surveillance and evaluation of vitamin D nutrition and its health impact in chinese older adults. J Nutr. (2025) 155:1031–40. doi: 10.1016/j.tjnut.2025.01.030
109. Yang A, Lv Q, Han Z, Dai S, Li Y, Hao M, et al. The effects of vitamin D on muscle strength are influenced by testosterone levels. J Cachexia Sarcopenia Muscle. (2025) 16:e13733. doi: 10.1002/jcsm.13733
110. Ren Q, Liang J, Su Y, Tian R, Wu J, Ge S, et al. A causal effect of serum 25(OH)D level on appendicular muscle mass: evidence from NHANES data and mendelian randomization analyses. J Cachexia Sarcopenia Muscle. (2025) 16:e13778. doi: 10.1002/jcsm.13778
111. Uberti F, Lattuada D, Morsanuto V, Nava U, Bolis G, Vacca G, et al. Vitamin D protects human endothelial cells from oxidative stress through the autophagic and survival pathways. J Clin Endocrinol Metab. (2014) 99:1367–74. doi: 10.1210/jc.2013-2103
112. Wee CL, Azemi AK, Mokhtar SS, Yahaya S, Yaacob NS, Rasool AHG, et al. Vitamin D deficiency enhances vascular oxidative stress, inflammation, and angiotensin II levels in the microcirculation of diabetic patients. Microvasc Res. (2023) 150:104574. doi: 10.1016/j.mvr.2023.104574
113. Renke G, Starling-Soares B, Baesso T, Petronio R, Aguiar D, Paes R, et al. Effects of vitamin D on cardiovascular risk and oxidative stress. Nutrients. (2023) 15(3):769. doi: 10.3390/nu15030769
114. Argano C, Torres A, Orlando V, Cangialosi V, Maggio D, Pollicino C, et al. Molecular insight into the role of vitamin D in immune-mediated inflammatory diseases. Int J Mol Sci. (2025) 26(10):4798. doi: 10.3390/ijms26104798
115. Krisnamurti DGB, Louisa M, Poerwaningsih EH, Tarigan TJE, Soetikno V, Wibowo H, et al. Vitamin D supplementation alleviates insulin resistance in prediabetic rats by modifying IRS-1 and PPARgamma/NF-kappaB expressions. Front Endocrinol (Lausanne). (2023) 14:1089298. doi: 10.3389/fendo.2023.1089298
116. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. (1996) 335:1–7. doi: 10.1056/NEJM199607043350101
117. White JP, Gao S, Puppa MJ, Sato S, Welle SL, Carson JA, et al. Testosterone regulation of Akt/mTORC1/FoxO3a signaling in skeletal muscle. Mol Cell Endocrinol. (2013) 365:174–86. doi: 10.1016/j.mce.2012.10.019
118. Enns DL and Tiidus PM. The influence of estrogen on skeletal muscle: sex matters. Sports Med. (2010) 40:41–58. doi: 10.2165/11319760-000000000-00000
119. Davezac M, Buscato M, Zahreddine R, Lacolley P, Henrion D, Lenfant F, et al. Estrogen receptor and vascular aging. Front Aging. (2021) 2:727380. doi: 10.3389/fragi.2021.727380
120. Thomson RL, Brinkworth GD, Noakes M, Clifton PM, Norman RJ, Buckley JD, et al. The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome. Hum Reprod. (2012) 27:2169–76. doi: 10.1093/humrep/des138
121. Zhang S, Feng H, Jiang JT, Feng SY, Jiang YJ, Chen GJ, et al. Liuwei Dihuang formula ameliorates perimenopausal atherosclerosis by modulating the microbiota-dependent TMA-TMAO metabolic axis. Phytomedicine. (2025) 148:157318. doi: 10.1016/j.phymed.2025.157318
122. Cappola AR, Auchus RJ, Fuleihan GEH, Handelsman DJ, Kalyani RR, McClung M, et al. Hormones and aging: an endocrine society scientific statement. J Clin Endocrinol Metab. (2023) 108:1835–74. doi: 10.1210/clinem/dgad225
123. O'Neill BT, Lauritzen HPMM, Hirshman MF, Smyth G, Goodyear LJ, Kahn CR, et al. Differential role of insulin/IGF-1 receptor signaling in muscle growth and glucose homeostasis. Cell Rep. (2015) 11:1220–35. doi: 10.1016/j.celrep.2015.04.037
124. Hamrick MW, Dukes A, Arounleut P, Davis C, Periyasamy-Thandavan S, Mork S, et al. The adipokine leptin mediates muscle- and liver-derived IGF-1 in aged mice. Exp Gerontol. (2015) 70:92–6. doi: 10.1016/j.exger.2015.07.014
125. Feng L, Li B, Xi Y, Cai M, and Tian Z. Aerobic exercise and resistance exercise alleviate skeletal muscle atrophy through IGF-1/IGF-1R-PI3K/Akt pathway in mice with myocardial infarction. Am J Physiol Cell Physiol. (2022) 322:C164–76. doi: 10.1152/ajpcell.00344.2021
126. Gagliano-Juca T and Basaria S. Testosterone replacement therapy and cardiovascular risk. Nat Rev Cardiol. (2019) 16:555–74. doi: 10.1038/s41569-019-0211-4
127. Chae JY, Lee GH, Lee SY, Jeong GS, Yun HY, Han EH, et al. Platycodin D reverses tumor necrosis factor-alpha-induced endothelial dysfunction by increasing nitric oxide through G protein-coupled estrogen receptor-mediated eNOS activity. Chem Biol Interact. (2025) 418:111577. doi: 10.1016/j.cbi.2025.111577
128. Tarantini S, Valcarcel-Ares NM, Yabluchanskiy A, Springo Z, Fulop GA, Ashpole N, et al. Insulin-like growth factor 1 deficiency exacerbates hypertension-induced cerebral microhemorrhages in mice, mimicking the aging phenotype. Aging Cell. (2017) 16:469–79. doi: 10.1111/acel.12583
129. Higashi Y, Pandey A, Goodwin B, and Delafontaine P. Insulin-like growth factor-1 regulates glutathione peroxidase expression and activity in vascular endothelial cells: Implications for atheroprotective actions of insulin-like growth factor-1. Biochim Biophys Acta. (2013) 1832:391–9. doi: 10.1016/j.bbadis.2012.12.005
130. Oury F, Sumara G, Sumara O, Ferron M, Chang HX, Smith CE, et al. Endocrine regulation of male fertility by the skeleton. Cell. (2011) 144:796–809. doi: 10.1016/j.cell.2011.02.004
131. Cui X, Li XD, Qi X, Wang DW, Kang BY, Li FJ, et al. Potential therapeutic role of sex steroids in treating sarcopenia: a network pharmacology and molecular dynamics study. BMC Pharmacol Toxicol. (2025) 26:155. doi: 10.1186/s40360-025-00978-0
132. Ohlsson C, Nethander M, Norlén A-K, Poutanen M, Gudmundsson EF, Aspelund T, et al. Serum DHEA and testosterone levels associate inversely with coronary artery calcification in elderly men. J Clin Endocrinol Metab. (2023) 108:3272–9. doi: 10.1210/clinem/dgad351
133. Blaauw R, Calder PC, Martindale RG, and Berge MM. Combining proteins with n-3 PUFAs (EPA + DHA) and their inflammation pro-resolution mediators for preservation of skeletal muscle mass. Crit Care. (2024) 28:38. doi: 10.1186/s13054-024-04803-8
134. Sun T, Ma Z, Gao L, Wang Y, and Xie H. Correlation between sarcopenia and arteriosclerosis in elderly community dwellers: A multicenter study. J Nutr Health Aging. (2021) 25:692–7. doi: 10.1007/s12603-021-1624-4
135. Joyce E. Frailty and cardiovascular disease: A two-way street? Cleve Clin J Med. (2018) 85:65–8. doi: 10.3949/ccjm.85a.17075
136. Zhang L, Guo Q, Feng B-L, Wang C-Y, Han P-P, Hu J, et al. A cross-sectional study of the association between arterial stiffness and sarcopenia in chinese community-dwelling elderly using the asian working group for sarcopenia criteria. J Nutr Health Aging. (2019) 23:195–201. doi: 10.1007/s12603-018-1147-9
137. Hogan AE, Davis C, Jenkins BJ, Jones N, and O'Shea D. Repurposing metabolic drugs as anti-inflammatory agents. Trends Endocrinol Metab. (2025) S1043-2760(25)00149-3. doi: 10.1016/j.tem.2025.07.003
138. Cosentino N, Trombara F, De Metrio M, Molinari C, Genovese S, Pontone G, et al. Cardiovascular protection in coronary artery disease: mechanistic and clinical insights into SGLT2 inhibitors and GLP-1 receptor agonists. Pharm (Basel). (2025) 18(8):1202. doi: 10.3390/ph18081202
139. Kalaitzoglou E. Diabetes pharmacotherapy and effects on the musculoskeletal system. Diabetes Metab Res Rev. (2019) 35:e3100. doi: 10.1002/dmrr.3100
140. Kalaitzoglou E, Fowlkes JL, Popescu I, and Thrailkill KM. GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform? Acta Diabetol. (2023) 60:1441–8. doi: 10.1007/s00592-023-02124-w
141. Kaneto H, Obata A, Kimura T, Shimoda M, Okauchi S, Shimo N, et al. Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic beta-cell function and reduction of insulin resistance. J Diabetes. (2017) 9:219–25. doi: 10.1111/1753-0407.12494
142. Holten MK, Zacho M, Gaster M, Juel C, Wojtaszewski JFP, Dela F, et al. Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes. (2004) 53:294–305. doi: 10.2337/diabetes.53.2.294
143. Turcotte LP and Fisher JS. Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. Phys Ther. (2008) 88:1279–96. doi: 10.2522/ptj.20080018
144. Kido K, Sase K, Yokokawa T, and Fujita S. Enhanced skeletal muscle insulin sensitivity after acute resistance-type exercise is upregulated by rapamycin-sensitive mTOR complex 1 inhibition. Sci Rep. (2020) 10:8509. doi: 10.1038/s41598-020-65397-z
145. Hawley JA, Hargreaves M, Joyner MJ, and Zierath JR. Integrative biology of exercise. Cell. (2014) 159:738–49. doi: 10.1016/j.cell.2014.10.029
146. Egan B and Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab. (2013) 17:162–84. doi: 10.1016/j.cmet.2012.12.012
147. Kido K, Ato S, Yokokawa T, Makanae Y, Sato K, Fujita S, et al. Acute resistance exercise-induced IGF1 expression and subsequent GLUT4 translocation. Physiol Rep. (2016) 4. doi: 10.14814/phy2.12907
148. Green DJ, Maiorana A, O'Driscoll G, and Taylor R. Effect of exercise training on endothelium-derived nitric oxide function in humans. J Physiol. (2004) 561:1–25. doi: 10.1113/jphysiol.2004.068197
149. Huh JY, Dincer F, Mesfum E, and Mantzoros CS. Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans. Int J Obes (Lond). (2014) 38:1538–44. doi: 10.1038/ijo.2014.42
150. Liao C-D, Tsauo J-Y, Huang S-W, Ku J-W, Hsiao D-J, Liou T-H, et al. Effects of elastic band exercise on lean mass and physical capacity in older women with sarcopenic obesity: A randomized controlled trial. Sci Rep. (2018) 8:2317. doi: 10.1038/s41598-018-20677-7
151. Palmefors H, DuttaRoy S, Rundqvist B, and Börjesson M. The effect of physical activity or exercise on key biomarkers in atherosclerosis–a systematic review. Atherosclerosis. (2014) 235:150–61. doi: 10.1016/j.atherosclerosis.2014.04.026
152. Isenberg BC, Dimilla PA, Walker M, Kim S, and Wong JY. Vascular smooth muscle cell durotaxis depends on substrate stiffness gradient strength. Biophys J. (2009) 97:1313–22. doi: 10.1016/j.bpj.2009.06.021
153. Sardeli AV, Tomeleri CM, Cyrino ES, Fernhall B, Cavaglieri CB, Chacon-Mikahil MPT, et al. Effect of resistance training on inflammatory markers of older adults: A meta-analysis. Exp Gerontol. (2018) 111:188–96. doi: 10.1016/j.exger.2018.07.021
154. Fan Y, Hu CC, Xie XX, Weng YF, Chen C, Wang ZK, et al. Effects of diets on risks of cancer and the mediating role of metabolites. Nat Commun. (2024) 15:5903. doi: 10.1038/s41467-024-50258-4
155. Li S, Tan Y, Liu S, and Li C. Preventive potential of chitosan self-assembled coconut residue dietary fiber in hyperlipidemia: Mechanistic insights into gut microbiota and short-chain fatty acids. J Food Sci. (2024) 89:9968–84. doi: 10.1111/1750-3841.17513
156. Damasceno JV, Garcez A, Alves AA, Rosa da Mata I, Dal Bosco SM, Garavaglia J, et al. Effects of daily extra virgin olive oil consumption on biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. (2026) 66(2):392–408. doi: 10.1080/10408398
157. Pozzetti L, Ferrara F, Marotta L, Gemma S, Butini S, Benedusi M, et al. Extra virgin olive oil extracts of indigenous southern tuscany cultivar act as anti-inflammatory and vasorelaxant nutraceuticals. Antioxidants (Basel). (2022) 11(3):437. doi: 10.3390/antiox11030437
158. Salucci S, Bartoletti-Stella A, Bavelloni A, Aramini B, Blalock WL, Fabbri F, et al. Extra virgin olive oil (EVOO), a mediterranean diet component, in the management of muscle mass and function preservation. Nutrients. (2022) 14(17):3567. doi: 10.3390/nu14173567
159. Singh RB, Nabavizadeh F, Fedacko J, Pella D, Vanova N, Jakabcin P, et al. Dietary approaches to stop hypertension via indo-mediterranean foods, may be superior to DASH diet intervention. Nutrients. (2022) 15(1):46. doi: 10.3390/nu15010046
160. Kim JW and Yang SJ. Dietary patterns, kidney function, and sarcopenia in chronic kidney disease. Nutrients. (2025) 17. doi: 10.3390/nu17030404
161. Dina C, Tit DM, Radu A, Bungau G, and Radu A-F. Obesity, dietary patterns, and cardiovascular disease: A narrative review of metabolic and molecular pathways. Curr Issues Mol Biol. (2025) 47. doi: 10.3390/cimb47060440
162. Jäger R, Heileson JL, Abou Sawan S, Dickerson BL, Leonard M, Kreider RB, et al. International society of sports nutrition position stand: long-chain omega-3 polyunsaturated fatty acids. J Int Soc Sports Nutr. (2025) 22:2441775. doi: 10.1080/15502783.2024.2441775
163. Zeppieri M, Gagliano C, D'Esposito F, Musa M, Gattazzo I, Zanella MS, et al. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA): A targeted antioxidant strategy to counter oxidative stress in retinopathy. Antioxidants (Basel). (2024) 14(1):6. doi: 10.3390/antiox14010006
164. Wu ZJ, Wu ZJ, Li YC, Zheng Y, Zhou MQ, Li H, et al. Differential effects of EPA and DHA on aging-related sarcopenia in mice and possible mechanisms involved. Food Funct. (2025) 16:601–16. doi: 10.1039/D4FO04341C
165. Kelley DS and Adkins Y. Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis in human subjects. Proc Nutr Soc. (2012) 71:322–31. doi: 10.1017/S0029665112000080
166. Aragon AA, Tipton KD, and Schoenfeld BJ. Age-related muscle anabolic resistance: inevitable or preventable? Nutr Rev. (2023) 81:441–54. doi: 10.1093/nutrit/nuac062
167. Fuchs CJ, Hermans WJH, Holwerda AM, Smeets JSJ, Senden JM, Kranenburg JV, et al. Branched-chain amino acid and branched-chain ketoacid ingestion increases muscle protein synthesis rates in vivo in older adults: a double-blind, randomized trial. Am J Clin Nutr. (2019) 110:862–72. doi: 10.1093/ajcn/nqz120
168. Moro T, Brightwell CR, Velarde B, Fry CS, Nakayama K, Sanbongi C, et al. Whey protein hydrolysate increases amino acid uptake, mTORC1 signaling, and protein synthesis in skeletal muscle of healthy young men in a randomized crossover trial. J Nutr. (2019) 149:1149–58. doi: 10.1093/jn/nxz053
169. McGarrah RW and White PJ. Branched-chain amino acids in cardiovascular disease. Nat Rev Cardiol. (2023) 20:77–89. doi: 10.1038/s41569-022-00760-3
170. Al-Habsi N, Al-Khalili M, Haque SA, Elias M, Olqi NA, Uraimi TA, et al. Health benefits of prebiotics, probiotics, synbiotics, and postbiotics. Nutrients. (2024) 16(22):3955. doi: 10.3390/nu16223955
171. Xu T, Wu XY, Liu J, Sun JY, Wang XB, Fan G, et al. The regulatory roles of dietary fibers on host health via gut microbiota-derived short chain fatty acids. Curr Opin Pharmacol. (2022) 62:36–42. doi: 10.1016/j.coph.2021.11.001
172. Mann ER, Lam YK, and Uhlig HH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol. (2024) 24:577–95. doi: 10.1038/s41577-024-01014-8
173. Cantorna MT and Arora J. Two lineages of immune cells that differentially express the vitamin D receptor. J Steroid Biochem Mol Biol. (2023) 228:106253. doi: 10.1016/j.jsbmb.2023.106253
174. Zhou A and Hypponen E. Vitamin D deficiency and C-reactive protein: a bidirectional Mendelian randomization study. Int J Epidemiol. (2023) 52:260–71. doi: 10.1093/ije/dyac087
175. Pal E, Ungvári Z, Benyó Z, and Várbíró S. Role of vitamin D deficiency in the pathogenesis of cardiovascular and cerebrovascular diseases. Nutrients. (2023) 15(2):334. doi: 10.3390/nu15020334
176. Charoenporn V, Tungsukruthai P, Teacharushatakit P, Hanvivattanakul S, Sriyakul K, Sukprasert S, et al. Effects of an 8-week high-dose vitamin D supplementation on fatigue and neuropsychiatric manifestations in post-COVID syndrome: A randomized controlled trial. Psychiatry Clin Neurosci. (2024) 78:595–604. doi: 10.1111/pcn.13716
177. Pinto T, Aires A, Cosme F, Bacelar E, Morais MC, Oliveira I, et al. Bioactive (Poly)phenols, volatile compounds from vegetables, medicinal and aromatic plants. Foods. (2021) 10(1):106. doi: 10.3390/foods10010106
178. Huang M, Xie XN, Yuan R, Xin QQ, Ma SD, Guo HG, et al. The multifaceted anti-atherosclerotic properties of herbal flavonoids: A comprehensive review. Pharmacol Res. (2025) 211:107551. doi: 10.1016/j.phrs.2024.107551
179. Yadav R, Mishra S, Chaturvedi R, and Pandey A. Therapeutic potential of curcumin in cardiovascular disease: Targeting atherosclerosis pathophysiology. BioMed Pharmacother. (2025) 190:118412. doi: 10.1016/j.biopha.2025.118412
180. Cohen S, Nathan JA, and Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov. (2015) 14:58–74. doi: 10.1038/nrd4467
181. Farid M, Reid MB, Li YP, Gerken E, and Durham WJ. Effects of dietary curcumin or N-acetylcysteine on NF-kappaB activity and contractile performance in ambulatory and unloaded murine soleus. Nutr Metab (Lond). (2005) 2:20. doi: 10.1186/1743-7075-2-20
182. Unal G, Xie YQ, and Fussenegger M. A closed-loop cholesterol shunt controlling experimental dyslipidemia. Cell Metab. (2025) 37(10):2066–75. doi: 10.1016/j.cmet.2025.08.011
183. Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. (2024) 390:1770–80. doi: 10.1056/NEJMoa2402309
184. Scoditti E, Tumolo MR, and Garbarino S. Mediterranean diet on sleep: A health alliance. Nutrients. (2022) 14(14):2998. doi: 10.3390/nu14142998
185. Perry CA, Van Guilder GP, and Butterick TA. Decreased myostatin in response to a controlled DASH diet is associated with improved body composition and cardiometabolic biomarkers in older adults: results from a controlled-feeding diet intervention study. BMC Nutr. (2022) 8:24. doi: 10.1186/s40795-022-00516-9
186. Wang Q, Zhao X, Wang W, Chen XL, and Lu SB. Identification of novel biomarkers and drug targets for frailty-related skeletal muscle aging: a multi-omics study. QJM. (2025) 118(9):657–77. doi: 10.1093/qjmed/hcaf108
187. Andreux PA, Blanco-Bose B, Ryu D, Burdet F, Ibberson M, Aebischer P, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. (2019) 1:595–603. doi: 10.1038/s42255-019-0073-4
188. Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. (2021) 372:1224–9. doi: 10.1126/science.abe9985
Keywords: aging, atherosclerosis, inflammaging, insulin resistance, sarcopenia
Citation: Yu M, Ge L, Fu C and Zhao R (2026) Unraveling the metabolic pathways between atherosclerosis and sarcopenia. Front. Endocrinol. 16:1762825. doi: 10.3389/fendo.2025.1762825
Received: 08 December 2025; Accepted: 31 December 2025; Revised: 30 December 2025;
Published: 06 February 2026.
Edited by:
Antoni Sureda, University of the Balearic Islands, SpainReviewed by:
Elisa Dietrich, Sapienza University of Rome, ItalyLara Russo, National Research Council (CNR), Italy
Copyright © 2026 Yu, Ge, Fu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rujia Zhao, MTkxNTc5MjY1NzFAMTYzLmNvbQ==; Chen Fu, eG5mdWNoZW5AMTYzLmNvbQ==